Recent discussions on X regarding AngioDynamics (ANGO) have been sparked by a significant insider purchase, with the CEO reportedly acquiring $111,500 worth of shares. This move has caught the attention of investors, with many interpreting it as a strong signal of confidence in the company's future, especially following a recent earnings beat that saw the stock surge by nearly 10%. The conversation reflects a renewed interest in the medical technology firm's growth trajectory.
Additionally, chatter on X has touched on the company's clinical advancements, such as progress in trials and innovative platforms like the NanoKnife System, which some believe could drive long-term value. However, there are mixed opinions, with a few voices pointing to uncertainties around market competition and a recent downgrade by analysts to a hold rating. This blend of optimism and caution keeps the dialogue dynamic and engaging.
Note: This discussion summary was generated from an AI condensation of post data.
AngioDynamics Congressional Stock Trading
Members of Congress have traded $ANGO stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ANGO stock by members of Congress over the last 6 months:
- REPRESENTATIVE DEBBIE WASSERMAN SCHULTZ has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/27 and 1 sale worth up to $15,000 on 07/16.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
AngioDynamics Insider Trading Activity
AngioDynamics insiders have traded $ANGO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ANGO stock by insiders over the last 6 months:
- JAMES C CLEMMER (President and CEO) purchased 10,000 shares for an estimated $111,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AngioDynamics Hedge Fund Activity
We have seen 68 institutional investors add shares of AngioDynamics stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DIVISADERO STREET CAPITAL MANAGEMENT, LP added 2,435,365 shares (+253.7%) to their portfolio in Q2 2025, for an estimated $24,158,820
- POINT72 ASSET MANAGEMENT, L.P. added 1,020,239 shares (+109.9%) to their portfolio in Q2 2025, for an estimated $10,120,770
- ARMISTICE CAPITAL, LLC removed 566,185 shares (-27.0%) from their portfolio in Q2 2025, for an estimated $5,616,555
- MORGAN STANLEY removed 419,209 shares (-59.6%) from their portfolio in Q2 2025, for an estimated $4,158,553
- BASTION ASSET MANAGEMENT INC. added 304,217 shares (+46.5%) to their portfolio in Q2 2025, for an estimated $3,017,832
- INFORMED MOMENTUM CO LLC removed 290,550 shares (-86.6%) from their portfolio in Q2 2025, for an estimated $2,882,256
- JPMORGAN CHASE & CO removed 253,681 shares (-77.8%) from their portfolio in Q2 2025, for an estimated $2,516,515
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AngioDynamics Government Contracts
We have seen $75,000 of award payments to $ANGO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TISSUE ABLATION SYSTEM: $75,000
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
AngioDynamics Analyst Ratings
Wall Street analysts have issued reports on $ANGO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 07/16/2025
- HC Wainwright & Co. issued a "Buy" rating on 07/16/2025
To track analyst ratings and price targets for AngioDynamics, check out Quiver Quantitative's $ANGO forecast page.
AngioDynamics Price Targets
Multiple analysts have issued price targets for $ANGO recently. We have seen 3 analysts offer price targets for $ANGO in the last 6 months, with a median target of $18.0.
Here are some recent targets:
- William Plovanic from Canaccord Genuity set a target price of $18.0 on 10/03/2025
- Frank Takkinen from Lake Street set a target price of $24.0 on 07/16/2025
- Yi Chen from HC Wainwright & Co. set a target price of $16.0 on 07/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
